Alcobra Ltd. (NASDAQ:ADHD) was downgraded by stock analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research note issued on Friday.

A number of other research analysts have also recently commented on ADHD. Roth Capital set a $8.00 target price on shares of Alcobra and gave the stock a “buy” rating in a research report on Saturday, October 1st. Piper Jaffray Cos. cut shares of Alcobra from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $10.00 to $3.00 in a research report on Thursday, September 29th. Cantor Fitzgerald cut shares of Alcobra from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a research report on Thursday, September 29th. Zacks Investment Research raised shares of Alcobra from a “sell” rating to a “hold” rating in a research report on Tuesday, July 26th. Finally, Jefferies Group reissued a “buy” rating on shares of Alcobra in a research report on Thursday, August 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. Alcobra presently has an average rating of “Hold” and an average price target of $6.47.

Analyst Recommendations for Alcobra (NASDAQ:ADHD)

Shares of Alcobra (NASDAQ:ADHD) traded up 2.115% during mid-day trading on Friday, reaching $2.655. 260,209 shares of the company were exchanged. The company’s 50-day moving average is $4.41 and its 200 day moving average is $4.46. Alcobra has a 12 month low of $1.95 and a 12 month high of $8.78. The firm’s market capitalization is $73.18 million.

Alcobra (NASDAQ:ADHD) last posted its earnings results on Tuesday, August 30th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. Analysts predict that Alcobra will post ($0.94) EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. Franklin Resources Inc. raised its stake in Alcobra by 28.2% in the first quarter. Franklin Resources Inc. now owns 3,652,931 shares of the company’s stock valued at $13,845,000 after buying an additional 804,350 shares during the last quarter. VHCP Management II LLC raised its stake in Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock valued at $6,530,000 after buying an additional 323,902 shares during the last quarter. VHCP Management LLC raised its stake in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock valued at $2,799,000 after buying an additional 138,813 shares during the last quarter. BlackRock Fund Advisors raised its stake in Alcobra by 1.8% in the second quarter. BlackRock Fund Advisors now owns 361,130 shares of the company’s stock valued at $1,621,000 after buying an additional 6,516 shares during the last quarter. Finally, Palo Alto Investors LLC raised its stake in Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock valued at $1,225,000 after buying an additional 18,600 shares during the last quarter. Hedge funds and other institutional investors own 73.69% of the company’s stock.

Alcobra Company Profile

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

5 Day Chart for NASDAQ:ADHD

Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.